SD 169 (indole-5-carboxamide): Selective ATP-Competitive Inhibitor of p38 MAP Kinase

Executive Summary: SD 169 (indole-5-carboxamide) is a small-molecule, ATP-competitive inhibitor that selectively targets p38α and p38β MAP kinases, central mediators of cell stress responses (Qiao et al., 2024). The compound exhibits high purity (≥97%) and chemical stability when stored at -20°C (APExBIO). It has demonstrated efficacy in modulating inflammatory cytokine production, reducing T cell infiltration, and preserving pancreatic beta cell mass in NOD mouse models. SD 169 supports axonal regeneration by enhancing Schwann cell function and reducing TNF-mediated cell death. Its mechanism, selectivity, and solubility make it a benchmark tool for apoptosis assays, T cell modulation, and nerve injury research.

Biological Rationale

Protein kinases such as p38α and p38β are key regulators of cellular responses to stress, including inflammation, apoptosis, and differentiation (Qiao et al., 2024). The p38 MAPK pathway is activated by phosphorylation events in response to cytokines, UV irradiation, heat shock, and osmotic stress. Dysregulation of this pathway is associated with autoimmunity, neurodegeneration, and impaired cell survival. Selective inhibition of p38α/β has become a focus for therapeutic intervention in inflammatory and degenerative diseases. SD 169 (indole-5-carboxamide) was developed to provide high selectivity and potency for these kinase isoforms, minimizing off-target effects.

Mechanism of Action of SD 169 (indole-5-carboxamide)

SD 169 acts as an ATP-competitive inhibitor, binding to the active site of p38α and p38β MAP kinases. This prevents phosphorylation of downstream targets and interrupts the propagation of stress and inflammatory signals. Recent structural studies reveal that SD 169 stabilizes a specific inactive conformation of the p38α activation loop, rendering the phospho-threonine residue accessible to the WIP1 phosphatase (Qiao et al., 2024). This dual-action mechanism both blocks kinase activity and accelerates dephosphorylation, yielding potent pathway suppression. The specificity of SD 169 is driven by its indole-5-carboxamide scaffold, which confers high affinity for the p38 MAPK ATP-binding pocket and low cross-reactivity with other kinases (APExBIO).

Evidence & Benchmarks

• SD 169 (indole-5-carboxamide) demonstrates IC₅₀ values in the low nanomolar range for p38α/β kinases in cell-free assays, with minimal inhibition of unrelated kinases (Qiao et al., 2024).
• In non-obese diabetic (NOD) mouse models, SD 169 reduces p38 and HSP60 protein expression in T cells within pancreatic islets, leading to decreased T cell infiltration and improved beta cell survival (APExBIO).
• SD 169 treatment results in improved glucose homeostasis and preservation of beta cell mass in vivo (Qiao et al., 2024).
• The compound enhances axonal regeneration by increasing Schwann cell signaling and reducing TNF-induced Schwann cell apoptosis in nerve injury models (APExBIO).
• SD 169 is a crystalline solid (molecular weight 160.2, C9H8N2O) with solubility of 1.4 mg/ml in ethanol, 5 mg/ml in DMSO, and 16 mg/ml in dimethyl formamide. Purity is consistently ≥97% as verified by HPLC (APExBIO).

Applications, Limits & Misconceptions

SD 169 is widely used in apoptosis assays, inflammatory cytokine modulation, T cell function studies, and axonal regeneration research. It provides researchers with a reliable tool to dissect p38 MAPK signaling in both cell-based and animal models. For detailed scenario-driven protocols, see this scenario-guided resource, which SD 169’s evidence base and expands on assay reproducibility and workflow safety.

Compared to other selective ATP-competitive inhibitors, SD 169 (indole-5-carboxamide) offers higher purity and documented specificity for p38α/β. For a discussion on data quality and selectivity challenges, see this report; the current article clarifies mechanistic data and new in vivo benchmarks.

Common Pitfalls or Misconceptions

• SD 169 is not a pan-kinase inhibitor; it does not inhibit ERK or JNK MAP kinases at relevant concentrations.
• It is not effective in models where p38-independent pathways drive cytokine production or apoptosis.
• Long-term solutions of SD 169 are unstable at room temperature or above 4°C; use freshly prepared aliquots for reproducibility.
• SD 169 efficacy may vary in species or cell lines with altered ATP levels or unique kinase mutations.
• Misinterpretation of off-target effects is possible if purity or concentration controls are not rigorously maintained.

Workflow Integration & Parameters

SD 169 (indole-5-carboxamide) is supplied as a crystalline solid and should be stored at -20°C for optimal stability. It is soluble up to 1.4 mg/ml in ethanol, 5 mg/ml in DMSO, and 16 mg/ml in dimethyl formamide (APExBIO). Prepare solutions immediately before use; avoid repeated freeze-thaw cycles. Recommended concentrations for cell-based assays are typically 0.1–10 μM, based on target kinase expression and cell type. For in vivo studies, dosing regimens should be established based on pharmacokinetics and pilot titrations. Shipping is performed on blue ice for small molecules, ensuring compound integrity. For expanded discussion on assay integration and troubleshooting, see this article, which this dossier updates with new solubility and stability data.

For more information or to order the C5850 kit, visit the SD 169 (indole-5-carboxamide) product page.

Conclusion & Outlook

SD 169 (indole-5-carboxamide) is a validated, selective ATP-competitive inhibitor of p38α and p38β MAP kinases. Its dual-action mechanism and high chemical purity make it an essential tool for dissecting inflammatory, apoptotic, and regenerative signaling pathways. The compound’s robust benchmarks, as documented by APExBIO and recent peer-reviewed studies, underpin its value in both fundamental and preclinical research. Future work may extend its applications to additional disease models and combination therapy screening. For further context on its role in nerve regeneration and apoptosis research, see this related review, which this article extends by providing updated mechanistic insights and stability data.